Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 13Carcinoma, Hepatocellular 7Carcinoma, Renal Cell 4Lymphoma 3Endometrial Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Breast Neoplasms 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1

Interventions

lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × First-line Treatment × lenvatinib × Clear all
NCT05221775 2022-02-03

Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Tianjin Medical University Cancer Institute and Hospital

Phase 1 Unknown
18 enrolled
Gastrointestinal

First-line Treatment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡